NCT02426723已完成1 期
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
JW Pharmaceutical5 个研究点 分布在 2 个国家目标入组 25 人开始时间: 2015年10月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 5
- 主要终点
- Recommended dose of Phase 2 trial of CWP232291
研究概览
简要总结
This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or refractory MM:
- Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review Committee (SRC).
- Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding followed by cohort expansion at the combination therapy MTD or optimal dose as determined by the SRC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and then sign an informed consent form (ICF) prior to initiation of any study-specific procedure and treatment.
- •≥ 18 years of age.
- •Confirmed measurable MM based on the following:
- •Serum M component (≥ 0.5 g/dL), or
- •Urine M protein ≥ 200 mg/24 hours), or
- •Serum immunoglobulin free light chains ≥ 10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio), or
- •Non-secretory disease measurable with bone marrow biopsy or radiography.
- •Failed 2 or more prior standard MM therapies, and >100 days post autologous bone marrow transplant prior to first dose for transplanted subjects. Prior lenalidomide is permitted.
- •In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be ≥ 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Persistent clinically significant toxicities from prior chemotherapy or radiotherapy must not be greater than Grade
- •Eastern Cooperative Oncology Group (ECOG) performance score 0-2 (Appendix 3).
- •Adequate bone marrow function:
- •Absolute neutrophil count (ANC) ≥ 1000/mm3, independent of growth factor support;
- •Platelet count ≥ 75,000/mm3;
- •Hb ≥ 9 g/dL (independent of transfusions or erythropoiesis-stimulating agents [ESA]).
- •Adequate renal function:
- •Serum creatinine ≤ 2.5 mg/dL;
- •Creatinine clearance (CrCl) ≥ 60 mL/minute (Cockcroft-Gault).
- •Adequate hepatic function:
- •Total bilirubin < 2.5 x upper limit of normal (ULN); direct bilirubin < 2 x ULN for Gilbert's syndrome;
- •Alkaline phosphatase (AP) ≤ 2.5 x ULN, unless considered due to organ leukemic involvement;
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN.
- •Women of child-bearing potential (ie, women who are premenopausal or not surgically sterile):
- •Two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 4 weeks after discontinuing study drugs, and
- •Negative serum or urine pregnancy tests during screening and then within 3 days prior to Day
- •Sexually active men - effective contraceptive methods in subject and partner from the time of informed consent and until ≥ 4 weeks after discontinuing study drugs.
- •Able to adhere to the study visit schedule and other protocol requirements.
排除标准
- •Chemotherapy or immunotherapy < 5 half-lives prior to screening.
- •Not recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening.
- •Systemic corticosteroids < 1 week prior to Day 1 in Phase 1a. Subjects may receive stable physiologic replacement doses of glucocorticoids (up to the equivalent of 10 mg daily prednisone) as maintenance therapy for adrenal insufficiency.
- •Uncontrolled intercurrent illness including infections and psychiatric illness/social situations that may limit compliance with protocol requirements or the evaluation of study drugs.
- •Active cardiovascular disease including myocardial infarction (MI) < 6 months of screening, symptomatic coronary artery disease (CAD), arrhythmias, hypertension, or heart failure not controlled by medication.
- •History of deep venous thrombosis and pulmonary embolism (Phase 1b).
- •Anticoagulants < 7 days prior to Day
- •Aspirin is permitted in Phase 1b per standard of care with lenalidomide-based therapy.
- •Active central nervous system (CNS) disease.
- •Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
- •Pregnant or nursing women.
- •History of hypersensitivity to lenalidomide (Part B only)
- •History of other active malignancies < 3 years prior to screening except basal cell carcinoma, low grade Gleason score ≤ 6 prostate cancer that has been removed with undetectable prostate-specific antigen (PSA), and in situ cervical carcinoma.
研究组 & 干预措施
CWP232291
Experimental
Phase 1a: single administration of CWP232291 ,
Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone
干预措施: Phase 1a: CWP232291 (Drug)
CWP232291
Experimental
Phase 1a: single administration of CWP232291 ,
Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone
干预措施: Phase 1b: CWP232291, Lenalidomide, Dexamethasone (Drug)
结局指标
主要结局
Recommended dose of Phase 2 trial of CWP232291
时间窗: up to 4 weeks
次要结局
- Cmax as a pharmacokinetic parameter of 'CWP232291'(Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion)
- AUC as a pharmacokinetic parameter of 'CWP232291'(Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion)
- Cmax as a pharmacokinetic parameter of metabolites of ' CWP232204'(Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion)
- AUC as a pharmacokinetic parameter of metabolites of ' CWP232204'(Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion)
研究者
研究点 (5)
Loading locations...
相似试验
终止
1 期
AHN-12 Biodistribution in Advanced LeukemiaAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelogenous LeukemiaNCT01207076Masonic Cancer Center, University of Minnesota8
已完成
1 期
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult VolunteersHealth, SubjectiveNCT05009368Celltrion41
已完成
1 期
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult VolunteersHealth, SubjectiveNCT05002244Celltrion37
招募中
1 期
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsOncologyMEK MutationRAF Gene MutationRas (KRAS or NRAS) Gene MutationSolid Tumor, AdultMAPK Pathway Gene MutationMelanomaGliomaNSCLCNCT06326411Nested Therapeutics, Inc230
终止
2 期
Obeticholic Acid in Pediatric Subjects With Biliary AtresiaBiliary AtresiaNCT05321524Intercept Pharmaceuticals7